Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 3Graft vs Host Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 88fludarabine phosphate 77Busulfan 56Tacrolimus 54Mycophenolic Acid 54Antilymphocyte Serum 48Peripheral Blood Stem Cell Transplantation 46Filgrastim 42Melphalan 41Cyclosporine 39Whole-Body Irradiation 38fludarabine 36Radiotherapy 32Methotrexate 28Cord Blood Stem Cell Transplantation 25Methylprednisolone 24Alemtuzumab 17Etoposide 16Thiotepa 15Rituximab 14Cytarabine 14thymoglobulin 13Granulocyte Colony-Stimulating Factor 12Stem Cell Transplantation 10sargramostim 9Sirolimus 9Flow Cytometry 9Psychiatric Rehabilitation 8Prednisone 7Mesna 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Calcineurin Inhibitors × Myeloid × Clear all
NCT05515029 2023-09-28

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Active not recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡